You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letters
Riboflavin/ultravoilet light-mediated crosslinking for fungal keratitis
  1. Zhiwei Li1,
  2. Vishal Jhanji2,3,
  3. Xiangchen Tao1,
  4. Haiqun Yu1,
  5. Wei Chen4,
  6. Guoying Mu1
  1. 1 Department of Ophthalmology, Provincial Hospital affiliated to Shandong University, Jinan, China
  2. 2 Department of Visual Sciences and Ophthalmology, the Chinese University of Hong Kong, Kowloon, Hong Kong
  3. 3 Centre for Eye Research Australia, University of Melbourne, Australia
  4. 4 Clinical College of Ophthalmology, Tianjin Medical Univeristy, Tianjin, China
  1. Correspondence to Dr Guoying Mu, Department of Ophthalmology, Provincial Hospital affiliated to Shandong University, No. 324, Jing 5 Road, Ji'nan City, Shandong Province, P. R. China, 250021; mgyeyes{at}yahoo.com.cn

https://doi.org/10.1136/bjophthalmol-2012-302518

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Introduction

    Collagen crosslinking (CXL) has been used to treat cases with bacterial, Acanthamoeba 1 ,2 and fungal keratitis2 with encouraging results. In this study, we present the clinical outcomes in cases with fungal keratitis that received riboflavin/ultravoilet light A (UVA) light-mediated crosslinking.

    Methods

    Patients with microbiologically proven fungal keratitis were included in this study. A written consent was obtained from all the patients. The study protocol was approved by the ethics committee of the Provincial Hospital. Initial treatment was commenced in the form of hourly 5% natamycin eye drops and 0.3% tobramycin eye drops four times a day. A decision was taken to perform CXL after no response to treatment or an exacerbation of infection was observed. Under topical anaesthesia, the epithelium surrounding the infiltrate was removed. Riboflavin (Medio-Cross riboflavin/dextran solution, 0.1%) was administered topically for 30 min at intervals of 2 min. The cornea was illuminated for 30 min using a UV light lamp (UV-X 1000 system, IROC Innocross AG Co, Switzerland; wavelength 365 nm, irradiance 3 mW/cm2, total dose 5.4 J/cm2). Riboflavin administration was …

    View Full Text

    Footnotes

    • Contributors Concept and design: ZL and VJ. Analysis and interpretation: ZL and VJ. Writing the article: ZL, VJ, XT, HY, WC and GM. Critical revision of the article: ZL and VJ. Final approval of the article: ZL, VJ, XT, HY, WC and GM. Data collection: ZL. Provision of materials, patients or resources: ZL, XT, HY, WC and GM. Statistical expertise: ZL and VJ. Obtaining funding: ZL and GM. Literature search: ZL and VJ.

    • Funding This study was supported by the Natural Science Foundation of Shandong Province (ZR2012HM008).

    • Competing interests None.

    • Patient consent Obtained.

    • Ethics approval The ethic committee of the Provincial Hospital affiliated to Shandong University.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • ▸ Additional material is published online only. To view please visit the journal online (http://dx.doi.org/10.1136/bjophthalmol-2012-302518).